Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
Spur Therapeutics on Tuesday said it has treated the first Gaucher disease patient with its investigational gene therapy, FLT201 (avigbagene parvec), in a pivotal trial. In the Phase III GALILEO-3 ...
The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.
The British company is developing two ADCs against B7-H3 and HER2 using a novel payload it is betting can overcome resistance to other ADCs.
The firm recently advanced its first candidate into clinical testing, evaluating STX-1150 as a treatment for hypercholesterolemia.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
NEW YORK – Roche will share with regulators data from a Phase III trial of its KRAS G12C inhibitor divarasib, showing its ability to keep lung cancer patients alive longer without progression compared ...
Three cases suggest some clinicians lack understanding of relatively common autosomal recessive disorders and are ...
NEW YORK – The earliest CAR T-cell therapies are starting to hit decade milestones, and despite their success, their developers say it's worth it to keep asking questions about safety and efficacy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results